| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/LEU.2012.74 |
| P698 | PubMed publication ID | 22425895 |
| P50 | author | Michael C. Heinrich | Q40526741 |
| Jeffrey W. Tyner | Q42182973 | ||
| P2093 | author name string | G Fan | |
| D Nelson | |||
| J Dunlap | |||
| A Warrick | |||
| M M Loriaux | |||
| C L Corless | |||
| T L Neff | |||
| C Beadling | |||
| T Bains | |||
| P2860 | cites work | Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia | Q34213539 |
| Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias | Q34973772 | ||
| Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry | Q35169273 | ||
| Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models | Q37142178 | ||
| JAK mutations in high-risk childhood acute lymphoblastic leukemia | Q37224111 | ||
| Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. | Q37300183 | ||
| ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon | Q38346345 | ||
| Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors | Q39570279 | ||
| Activating mutations in human acute megakaryoblastic leukemia. | Q39945867 | ||
| Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome | Q39993986 | ||
| Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia | Q39999145 | ||
| Activating alleles of JAK3 in acute megakaryoblastic leukemia | Q40255542 | ||
| Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers | Q45344494 | ||
| The specificity of JAK3 kinase inhibitors | Q46840578 | ||
| Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. | Q54657102 | ||
| P433 | issue | 9 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 2144-2146 | |
| P577 | publication date | 2012-03-19 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. | |
| P478 | volume | 26 |
| Q41660964 | Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia |
| Q101226635 | Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo |
| Q44498168 | Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. |
| Q38965035 | CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress. |
| Q35075158 | Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia |
| Q38763094 | Development of Selective Covalent Janus Kinase 3 Inhibitors. |
| Q38201143 | Disease-specific mutations in mature lymphoid neoplasms: recent advances |
| Q36323519 | Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities |
| Q93027164 | Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia |
| Q35072638 | Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia. |
| Q41407670 | Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival |
| Q41000106 | Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia |
| Q39237403 | HiJAKing the epigenome in leukemia and lymphoma |
| Q57566523 | IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update |
| Q33798544 | Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia |
| Q37695012 | Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies |
| Q26782539 | JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications |
| Q42330161 | MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. |
| Q90238190 | MicroRNAs and their involvement in T-ALL: A brief overview |
| Q56965905 | Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia |
| Q50055394 | Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma |
| Q35692410 | PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. |
| Q34490429 | Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation |
| Q37140482 | RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications |
| Q44535044 | Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan |
| Q52647036 | Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. |
| Q49887894 | Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products. |
| Q45062542 | The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. |
| Q38856941 | Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment |
Search more.